CD274 and non-small cell lung carcinoma: The second phase of the study will evaluate the safety and efficacy of the combination of cobolimab with the anti-PD-1 blocking antibody dostarlimab in disease-specific cohorts including patients with NSCLC who received previous PD-L1 blockade immunotherapy and colorectal cancer patients with previous treatments.